It is trading at $124.94 a bit higher than the 50 day moving average of $112.16 and a tad higher than the 200 day moving average of $122.31. The 50 day moving average went up $12.78 or +11.40% and the 200 day average moved up $2.63. Alexion Pharmaceuticals, Inc. shares had a trading volume of 1,353K on Thursday. Volume was down 76.21% under the stocks average daily volume.
Traders are a little more bearish on Alexion Pharmaceuticals, Inc. of late if you take a look at the increase in short interest. The firm saw a rise in short interest of 10.90% between June 15, 2017 and May 31, 2017. Short shares increased from 4,001,349 to 4,437,499 over that timeframe. The days to cover increased to 1.2 and the short interest percentage is 0.02% as of May 31.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been the object of insider selling activity recently. Julie O’neill, EVP disclosed the sale of 651 shares. The shares were sold on March 2nd for an average price of $133.80. O’neill now owns $5,066,203 of the stock according to the SEC filing. Clare Carmichael, EVP let go of $287,192 worth of shares at a price of $131.80 on Wed the 1st. Carmichael now owns $5,161,420 of stock as reported to the SEC.
Sr VP Heidi L. Wagner sold 994 shares at a price of $131.80 on March 1st. That brings the Sr VP’s holdings to $3,823,518 per an SEC filing yesterday.
Here are some other firms who have updated their holdings. Piedmont Investment Advisors LLC expanded its investment by buying 401 shares an increase of 0.9%. Piedmont Investment Advisors LLC currently owns 46,087 shares worth $5,588,000. The total value of its holdings decreased 0.0%. As of quarter end Proficio Capital Partners LLC had acquired a total of 14 shares growing its stake by 8.6%. The value of the investment in ALXN went from $20,000 to $18,000 a change of 10.0% since the last quarter.
As of the end of the quarter Fny Partners Fund Lp had bought 495 shares growing its position 9,900.0%. The value of the company’s investment in Alexion Pharmaceuticals, Inc. increased from $1,000 to $60,000 increasing 5,900.0% quarter over quarter. Morgan Stanley cut its holdings by shedding 3,536 shares a decrease of 99.9% from 12/31/2016 to 03/31/2017. Morgan Stanley claims 4 shares with a value of $0. The value of the position overall is down by 100.0%.
On May 25, 2017 the stock rating was set at “Overweight” by Morgan Stanley up from the previous “Equal-Weight” rating. Equity analyst Oppenheimer released its first research report on the stock setting a rating of “Perform”.
On December 13 the company was rated “Equal-Weight” in a report from Morgan Stanley which is down from the previous “Overweight” rating. On November 29 the company was changed to a “Overweight” according to a Barclays report a boost from the previous “Equal-weight” rating.
On November 3, 2016 Deutsche Bank starting coverage on ALXN with an initial rating of “Buy”. On October 28 the company was set at “Market Perform” in a report from FBR Capital which was a boost from the previous “Underperform” rating.
The company is now up since yesterday’s close of $124.32. The company’s P/E ratio is 59.52 and the market cap of the company is 28.06B. In the latest earnings report the EPS was $2.10 and is expected to be $5.31 for the current year with 224,556,000 shares now outstanding. Next quarter’s EPS is forecasted to be $1.33 and the next full year EPS is anticipated to be $6.58.
Alexion Pharmaceuticals, Inc., launched on January 28, 1992, is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Business’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Business’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous)..